The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mukherjee, P.
Right arrow Articles by Gendler, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mukherjee, P.
Right arrow Articles by Gendler, S. J.
The Journal of Immunology, 00, 165: 3451-3460.
Copyright © 00 by The American Association of Immunologists

Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred1

Pinku Mukherjee, Amelia R. Ginardi, Cathy S. Madsen, Christopher J. Sterner, Melissa C. Adriance, Mary J. Tevethia and Sandra J. Gendler2

Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, AZ 85259

Pancreatic cancer is a highly aggressive, treatment refractory cancer and is the fourth leading cause of death in the United States. In humans, 90% of pancreatic adenocarcinomas overexpress altered forms of a tumor-specific Ag, mucin 1 (MUC1; an epithelial mucin glycoprotein), which is a potential target for immunotherapy. We have established a clinically relevant animal model for pancreatic cancer by developing a double transgenic mouse model (called MET) that expresses human MUC1 as self molecule and develops spontaneous tumors of the pancreas. These mice exhibit acinar cell dysplasia at birth, which progresses to microadenomas and acinar cell carcinomas. The tumors express large amounts of underglycosylated MUC1 similar to humans. Tumor-bearing MET mice develop low affinity MUC1-specific CTLs that have no effect on the spontaneously occurring pancreatic tumors in vivo. However, adoptive transfer of these CTLs was able to completely eradicate MUC1-expressing injectable tumors in MUC1 transgenic mice, and these mice developed long-term immunity. These CTLs were MHC class I restricted and recognized peptide epitopes in the immunodominant tandem repeat region of MUC1. The MET mice appropriately mimic the human condition and are an excellent model with which to elucidate the native immune responses that develop during tumor progression and to develop effective antitumor vaccine strategies.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
P. Mukherjee, G. D. Basu, T. L. Tinder, D. B. Subramani, J. M. Bradley, M. Arefayene, T. Skaar, and G. De Petris
Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition
J. Immunol., January 1, 2009; 182(1): 216 - 224.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. L. Tinder, D. B. Subramani, G. D. Basu, J. M. Bradley, J. Schettini, A. Million, T. Skaar, and P. Mukherjee
MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma
J. Immunol., September 1, 2008; 181(5): 3116 - 3125.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
G. Feldmann and A. Maitra
Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts
J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. L. Beatty, S. E. Plevy, A. R. Sepulveda, and O. J. Finn
Cutting Edge: Transgenic Expression of Human MUC1 in IL-10-/- Mice Accelerates Inflammatory Bowel Disease and Progression to Colon Cancer
J. Immunol., July 15, 2007; 179(2): 735 - 739.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. D. Basu, T. L. Tinder, J. M. Bradley, T. Tu, C. L. Hattrup, B. A. Pockaj, and P. Mukherjee
Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO
J. Immunol., August 15, 2006; 177(4): 2391 - 2402.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. I. Garbe, B. Vermeer, J. Gamrekelashvili, R. v. Wasielewski, F. R. Greten, A. M. Westendorf, J. Buer, R. M. Schmid, M. P. Manns, F. Korangy, et al.
Genetically Induced Pancreatic Adenocarcinoma Is Highly Immunogenic and Causes Spontaneous Tumor-Specific Immune Responses
Cancer Res., January 1, 2006; 66(1): 508 - 516.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Gerloni, P. Castiglioni, and M. Zanetti
The Cooperation between Two CD4 T Cells Induces Tumor Protective Immunity in MUC.1 Transgenic Mice
J. Immunol., November 15, 2005; 175(10): 6551 - 6559.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Dwyer, E. R. Bergert, M. K. O'Connor, S. J. Gendler, and J. C. Morris
In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter
Clin. Cancer Res., February 15, 2005; 11(4): 1483 - 1489.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
U. Karsten, N. Serttas, H. Paulsen, A. Danielczyk, and S. Goletz
Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1)
Glycobiology, August 1, 2004; 14(8): 681 - 692.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Xia, Y. Tanaka, S. Koido, C. Liu, P. Mukherjee, S. J. Gendler, and J. Gong
Prevention of Spontaneous Breast Carcinoma by Prophylactic Vaccination with Dendritic/Tumor Fusion Cells
J. Immunol., February 15, 2003; 170(4): 1980 - 1986.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. J. Cohen, N. Hoffmann, M. Farago, H. R. Hoogenboom, L. Eisenbach, and Y. Reiter
Direct Detection and Quantitation of a Distinct T-Cell Epitope Derived from Tumor-specific Epithelial Cell-associated Mucin Using Human Recombinant Antibodies Endowed with the Antigen-specific, Major Histocompatibility Complex-restricted Specificity of T Cells
Cancer Res., October 15, 2002; 62(20): 5835 - 5844.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. W. Wilkinson, E. L. Ross, D. Ellison, W. Zimmermann, D. Snary, and S. J. Mather
Evaluation of a Transgenic Mouse Model for Anti-Human CEA Radioimmunotherapeutics
J. Nucl. Med., October 1, 2002; 43(10): 1368 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. L. VanLith, K. G. Kohlgraf, C. L. Sivinski, R. M. Tempero, and M. A. Hollingsworth
MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses
Int. Immunol., August 1, 2002; 14(8): 873 - 882.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Schnurr, P. Galambos, C. Scholz, F. Then, M. Dauer, S. Endres, and A. Eigler
Tumor Cell Lysate-pulsed Human Dendritic Cells Induce a T-Cell Response against Pancreatic Carcinoma Cells: an in Vitro Model for the Assessment of Tumor Vaccines
Cancer Res., September 1, 2001; 61(17): 6445 - 6450.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. W. Wilkinson, E. L. Ross, R. Poulsom, M. Ilyas, J. Straub, D. Snary, W. F. Bodmer, and S. J. Mather
Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors
PNAS, August 17, 2001; (2001) 181353498.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. W. Wilkinson, E. L. Ross, R. Poulsom, M. Ilyas, J. Straub, D. Snary, W. F. Bodmer, and S. J. Mather
Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors
PNAS, August 28, 2001; 98(18): 10256 - 10260.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.